September 01, 2016

Theratechnologies Announces Commercialization Agreement For Tesamorelin In Spain And Portugal

Theratechnologies Inc. (TSX: TH) is pleased to announce that it has concluded agreements with Praxis Pharmaceutical, S.A. and its subsidiary PRX Pharma Produtos Farmacêuticos Unipessoal, LDA (“Praxis”) for the distribution and commercialization of EGRIFTA® (tesamorelin for injection) for the treatment of HIV-associated lipodystrophy in Spain and Portugal.